We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Roche Czech Republic

Pharmaceutical > Czech Republic > Roche Czech Republic
Change Company
Roche Czech Republic

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was

Read more »
Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

Buy all financials of Roche Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
              5,073 5,011 4,869 4,934 4,364    
              680 620 634 770 763    
              138 83.1 69.0 183 134    
              101 50.5 38.7 135 94.9    
              10.5% 4.85% 3.57% 11.5% 8.00%    
              2.72% 1.66% 1.42% 3.71% 3.07%    
              1.99% 1.01% 0.794% 2.73% 2.17%    
              226 220 216 216 202    

balance sheet

              2,473 2,238 2,344 2,245 2,317    
              386 329 354 338 334    
              2,085 1,971 1,988 1,905 1,962    
              1,015 1,065 1,104 1,239 1,134    
              1,458 1,173 1,240 1,006 1,183    
              0.949 1.46 0.000 0.000 0.000    
              1,451 1,163 1,231 978 1,168    
              1.67 -0.002 0.737 0.867 2.04    
              41.6% -0.035% 13.7% 23.0% 47.7%    
...             1.19% 0.316% -2.24% 0.681% 0.272%    

cash flow

              -232 65.2 159 127 66.8    
              -158 -65.5 -159 -127 -125    
              390 0.000 0.000 0.000 56.2    
              0.195 -0.286 -0.134 0.104 -2.04    

Download Data
income statement Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
              5,073 5,011 4,869 4,934 4,364    
              4,393 4,392 4,235 4,164 3,601    
              680 620 634 770 763    
              338 329 345 373 373    
              88.8 82.6 85.0 68.6 125    
              254 208 204 328 265    
              116 125 135 145 131    
              138 83.1 69.0 183 134    
              2.72 0.669 -1.69 1.48 1.12    
              0.000 0.000 0.000 0.000 0.000    
              135 82.4 70.7 182 133    
              34.2 31.9 32.0 46.9 38.1    
              0.000 0.000 0.000 0.000 0.000    
              101 50.5 38.7 135 94.9    

growth rates

...             4.27% -1.23% -2.83% 1.33% -11.5%    
...             -14.5% -3.47% 4.38% 2.78% 12.6%    
...             8.45% -18.2% -1.49% 60.6% -19.3%    
...             8.91% -39.8% -16.9% 165% -26.8%    
...             8.03% -39.1% -14.2% 157% -26.8%    
...             15.7% -50.1% -23.3% 248% -29.6%    

ratios

              10.5% 4.85% 3.57% 11.5% 8.00%    
...             8.06% 4.01% 3.25% 8.93% 5.39%    
              13.4% 12.4% 13.0% 15.6% 17.5%    
              5.00% 4.14% 4.20% 6.66% 6.07%    
              2.72% 1.66% 1.42% 3.71% 3.07%    
              1.99% 1.01% 0.794% 2.73% 2.17%    
...             1.19% 0.316% -2.24% 0.681% 0.272%    
              1.67 -0.002 0.737 0.867 2.04    

Download Data
balance sheet Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

balance sheet

              386 329 354 338 334    
              386 329 354 338 334    
              0.000 0.000 0.000 0.000 0.000    
              2,085 1,971 1,988 1,905 1,962    
              1,409 767 872 775 828    
              635 983 1,087 1,108 1,101    
              0.662 0.376 0.242 0.346 0.305    
              2,473 2,238 2,344 2,245 2,317    
              1,015 1,065 1,104 1,239 1,134    
              0.000 0.000 0.000 0.000 0.000    
              1,458 1,173 1,240 1,006 1,183    
              0.949 1.46 0.000 0.000 0.000    
              0.000 0.000 0.000 0.000 0.000    
              0.949 1.46 0.000 0.000 0.000    
              1,451 1,163 1,231 978 1,168    
              423 0.000 151 285 541    
              936 1,056 953 562 397    
              6.38 7.65 9.24 27.6 15.0    
              2,473 2,238 2,344 2,245 2,317    

growth rates

...             23.2% -9.52% 4.74% -4.23% 3.23%    
...             11.1% 4.97% 3.63% 12.2% -8.48%    
...             1,193% -100% -40,192% 88.9% 90.0%    
...           ... 1,177% -100% ... 88.9% 89.9%    

ratios

              423 0.000 151 285 541    
              422 -0.376 151 285 541    
              1,108 694 1,007 1,321 1,532    
              1,495 1,023 1,361 1,659 1,865    
              41.6% -0.035% 13.7% 23.0% 47.7%    
...             1.19% 0.316% -2.24% 0.681% 0.272%    

Download Data
cash flow Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

cash flow

              101 50.5 38.7 135 94.9    
              116 125 135 145 131    
...             -14.5 -524 297 161 51.9    
...             -434 414 -312 -314 -211    
              -232 65.2 159 127 66.8    
              -163 -77.6 -165 -143 -132    
              5.21 12.1 5.53 16.2 6.80    
              -158 -65.5 -159 -127 -125    
...             390 -423 151 134 256    
              390 0.000 0.000 0.000 56.2    
              0.195 -0.286 -0.134 0.104 -2.04    

ratios

              45.7 71.6 81.5 81.9 92.1    
              117 63.7 75.2 67.9 83.9    
              77.7 87.8 82.1 49.3 40.2    
              85.0 47.6 74.5 101 136    
              217 175 174 280 226    
              -390 -0.286 -0.134 0.104 -58.3    

Download Data
other data Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

other data

              4.52% 2.14% 1.69% 5.88% 4.16%    
              13.4% 12.4% 13.0% 15.6% 17.5%    
              226 220 216 216 202    
              6,520 7,054 6,805 7,362 7,192    
              124,598 124,765 133,116 144,043 153,708    
              6.85% 6.68% 7.19% 7.86% 8.81%    
              25.2% 38.8% 45.3% 25.8% 28.6%    
... ... ... ... ... ... ... ... ... ... ... ...    
              3.22% 1.55% 3.38% 2.90% 3.02%    
... ... ... ... ... ... ... ... ... ... ... 265    
... ... ... ... ... ... ... ... ... ... ... 6.08%    
              4,729 4,686 4,568 4,606 4,086    
              344 326 301 328 278    
...             3,721 3,630 3,533 3,806 3,192 ... ...
...             1,009 1,082 1,035 1,128 1,172 ... ...

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Roche Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Roche Czech Republic's performance between 2003 and 2016 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested

Read more »

This Annual Statistical Dossier offers a summary of Roche Czech Republic's performance between 2003 and 2016 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Roche Czech Republic at a Glance

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's

Read more »

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

This report offers a summary of the company's performance in 2003-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Roche Czech Republic in Numbers

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's

Read more »

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

This excel file offers a summary of the company's performance in 2003-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% when compared to the last year. Total sales reached CZK 4,962 mil, which is down 8.88% when compared to the previous year.

Historically, the company’s

Read more »

Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% when compared to the last year. Total sales reached CZK 4,962 mil, which is down 8.88% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 252 mil in 2016 and an all time low of CZK 16.8 mil in 2007.

In terms of sales, Roche Czech Republic reached an all time high of CZK 5,445 mil in 2015 and an all time low of CZK 2,879 mil in 2004.

Roche Czech Republic's net profit has grown 37.9% a year on average in the last five years while sales have increased by -0.198% a year since 2011.

The firm generated its shareholders an average return on invested capital of 6.60% in the last five years.

As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted a net profit and sales of CZK 73.4 mil and CZK 3,243 mil in 2016, Bayer Czech Republic generated a net profit of CZK 175 mil (with sales of CZK 4,326 mil) and Amgen Czech Republic netted CZK 31.5 mil (sales of CZK 626 mil).

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic made a net profit of CZK CZK 252 mil under revenues of CZK 4,962 mil in 2016, up 394% and -8.88%, respectively, when compared to the last year.

This translates into a net margin of 5.08%. Historically, the

Read more »

Roche Czech Republic made a net profit of CZK CZK 252 mil under revenues of CZK 4,962 mil in 2016, up 394% and -8.88%, respectively, when compared to the last year.

This translates into a net margin of 5.08%. Historically, the firm’s net margin reached an all time high of 5.08% in 2016 and an all time low of 0.126% in 2003. The average net margin in the last five years amounted to 2.34%.

On the operating level, EBITDA margin reached 7.10% and EBIT amounted to 9.57% of sales in 2016.

As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted net and EBITDA margin of 2.26% and 3.69%, respectively in 2016, Bayer Czech Republic generated margins of 4.04% and 5.38% and Amgen Czech Republic's profit margin reached 5.03% on the net and 6.20% on the EBITDA level in 2016.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic made a net profit of CZK 252 mil under revenues of CZK 4,962 mil in 2016, up 394% and -8.88%, respectively, when compared to the last year. This translates into a net margin of 5.08%.

Historically, the firm’s

Read more »

Roche Czech Republic made a net profit of CZK 252 mil under revenues of CZK 4,962 mil in 2016, up 394% and -8.88%, respectively, when compared to the last year. This translates into a net margin of 5.08%.

Historically, the firm’s net profit reached an all time high of CZK 252 mil in 2016 and an all time low of CZK 3.04 mil in 2003. Since 2011, the firm's net profit has increased 399% or 37.9% a year on average.

On the operating level, EBITDA reached CZK 475 mil, up 127% when compared to the previous year. Over the last five years, company's EBITDA has grown 18.0% a year on average.

As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted net and EBITDA margin of 2.26% and 3.69%, respectively in 2016, Bayer Czech Republic generated margins of 4.04% and 5.38% and Amgen Czech Republic's profit margin reached 5.03% on the net and 6.20% on the EBITDA level in 2016.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic's net debt reached CZK 203 mil and accounted for 14.2% of equity at the end of 2016. The ratio is down 74.6% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all

Read more »

Roche Czech Republic's net debt reached CZK 203 mil and accounted for 14.2% of equity at the end of 2016. The ratio is down 74.6% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 113% in 2004 and an all time low of -10.0% in 2003.

When compared to EBITDA, net debt amounted to 0.428x at the end of the year. The ratio reached an all time high of 4.29 in 2007 and an all time low of -0.170 in 2003.

As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted net debt to equity of -0.453%x and -0.047x when compared to EBITDA at the end of 2016. Bayer Czech Republic ended the year 2016 with a net debt at 128%x of equity and 1.98x when compared to its EBITDA while Bayer Czech Republic had net debt at 128%x of equity and 1.98x to EBITDA at the end of the year.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
Roche CR's net profit rose 394% to CZK 252 mil in 2016
Roche CR's net profit rose 394% to CZK 252 mil in 2016
Roche CR's employees rose 5.91% to 251 in 2016
Roche CR's Net Margin rose 442% to 5.08% in 2016
Roche CR's Total Cash From Operations rose 13,281% to CZK 621 mil in 2016
Roche CR's ROCE rose 382% to 12.8% in 2016
Roche CR's Capital Expenditures fell 2.81% to CZK 114 mil in 2016
Roche CR's Net Debt/EBITDA fell 86.4% to 0.428 in 2016
Roche CR's Cash & Cash Equivalents fell 71.7% to CZK 0.013 mil in 2016